{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:25:41Z","timestamp":1778149541130,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T00:00:00Z","timestamp":1310601600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Since transitional cell carcinoma (TCC) of the upper urinary tract is a relatively uncommon malignancy, the role of adjuvant radiotherapy is unknown.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We treated 133 patients with TCC of the renal pelvis or ureter at our institution between 1998 and 2008. The 67 patients who received external beam radiotherapy (EBRT) following surgery were assigned to the radiation group (RT). The clinical target volume included the renal fossa, the course of the ureter to the entire bladder, and the paracaval and para-aortic lymph nodes, which were at risk of harbouring metastatic disease in 53 patients. The tumour bed or residual tumour was targeted in 14 patients. The median radiation dose administered was 50 Gy. The 66 patients who received intravesical chemotherapy were assigned to the non-radiation group (non-RT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The overall survival rates for the RT and non-RT groups were not significantly different (p = 0.198). However, there was a significant difference between the survival rates for these groups based on patients with T3\/T4 stage cancer. A significant difference was observed in the bladder tumour relapse rate between the irradiated and non-irradiated bladder groups (p = 0.004). Multivariate analysis indicated that improved overall survival was associated with age &lt; 60 years, T1 or T2 stage, absence of synchronous LN metastases, and EBRT. Acute gastrointestinal and bladder reactions were the most common symptoms, but mild non-severe (&gt; grade 3) hematologic symptoms also occurred.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>EBRT may improve overall survival for patients with T3\/T4 cancer of the renal pelvis or ureter and delay bladder tumour recurrence in all patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-11-297","type":"journal-article","created":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T18:27:51Z","timestamp":1310668071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Radiotherapy may improve overall survival of patients with T3\/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse"],"prefix":"10.1186","volume":"11","author":[{"given":"Bing","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-Chong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zong-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-An","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong-Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,14]]},"reference":[{"issue":"s1","key":"2792_CR1","first-page":"s36","volume":"117","author":"EM Genega","year":"2002","unstructured":"Genega EM, Porter CR: Urothelial neoplasms of the kidney and ureter. An epidemiology, pathologic and clinical review. Am J Clin Pathol. 2002, 117 (s1): s36-48.","journal-title":"Am J Clin Pathol"},{"key":"2792_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/j.1464-410X.2006.06519.x","volume":"98","author":"RE Zigeuner","year":"2006","unstructured":"Zigeuner RE, Hutterer G, Chromecki T, Rehak P, Langner C: Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU International. 2006, 98: 1181-86,. 10.1111\/j.1464-410X.2006.06519.x.","journal-title":"BJU International"},{"key":"2792_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1464-410X.2008.07985.x","volume":"103","author":"LB Tan","year":"2008","unstructured":"Tan LB, Chang LL, Cheng KI, Huang CH, Kwan AL: Transitional cell carcinomas of the renal pelvis and the ureter: comparative demographic characteristics, pathological grade and stage and 5-year survival in a Taiwanese population. BJU International. 2008, 103: 312-16.","journal-title":"BJU International"},{"key":"2792_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1040-8428(03)00079-9","volume":"47","author":"Z Kirkali","year":"2003","unstructured":"Kirkali Z, Tuzel E: Transitional cell carcinoma of the ureter and renal pelvis. Critical Reviews in Oncol\/Hematology. 2003, 47: 155-69. 10.1016\/S1040-8428(03)00079-9.","journal-title":"Critical Reviews in Oncol\/Hematology"},{"key":"2792_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/ncpuro0875","volume":"4","author":"JD Raman","year":"2007","unstructured":"Raman JD, Scherr DS: Management of patients with upper urinary tract transitional cell carcinoma. Nature Clinical Practice Urology. 2007, 4: 432-443.","journal-title":"Nature Clinical Practice Urology"},{"key":"2792_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0959-8049(99)00012-X","volume":"35","author":"M Ozsahin","year":"1999","unstructured":"Ozsahin M, Zouhair A, Vill\u00e0 S, et al: Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. Eur J Cancer. 1999, 35: 738-43. 10.1016\/S0959-8049(99)00012-X.","journal-title":"Eur J Cancer"},{"key":"2792_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0022-5347(01)66563-7","volume":"155","author":"C Maulard-Durdux","year":"1996","unstructured":"Maulard-Durdux C, Dufour B, Hennequin C, et al: Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival?. J Urol. 1996, 155: 115-7.","journal-title":"J Urol"},{"key":"2792_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0360-3016(97)00773-6","volume":"41","author":"PW Grigsby","year":"1998","unstructured":"Grigsby PW: Carcinoma of the urethra in women. Int J Radiat Oncol Biol Phys. 1998, 41: 535-541. 10.1016\/S0360-3016(97)00773-6.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4 Pt 1","key":"2792_CR9","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/01.ju.0000137910.38441.8a","volume":"172","author":"B Czito","year":"2004","unstructured":"Czito B, Zietman A, Kaufman D, et al: Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol. 2004, 172 (4 Pt 1): 1271-1275.","journal-title":"J Urol"},{"key":"2792_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-1-4757-3656-4_37","volume-title":"AJCC cancer staging manual","author":"American Joint Committee on Cancer","year":"2002","unstructured":"American Joint Committee on Cancer: Renal pelvis and ureter. AJCC cancer staging manual. Edited by: Greene FL, et al. 2002, New York: Springer-Verlag, 329-334. 6","edition":"6"},{"key":"2792_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","volume":"47","author":"A Trotti","year":"2000","unstructured":"Trotti A, Byhardt R, Stetz J, et al: Common Toxicity Criteria (version 2.0): An improved reference for grading the acute effects of cancer treatment--Impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000, 47: 13-47. 10.1016\/S0360-3016(99)00559-3.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2792_CR12","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.eururo.2009.07.002","volume":"57","author":"JD Raman","year":"2009","unstructured":"Raman JD, Ng CK, Scherr DS, et al: Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. European Urol. 2009, 57: 1072-9.","journal-title":"European Urol"},{"key":"2792_CR13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0090-4295(99)80346-X","volume":"46","author":"SC Cozad","year":"1995","unstructured":"Cozad SC, Smalley SR, Austenfeld M, Noble M, Jennings S, Raymond R: Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure. Urology. 1995, 46: 796-800. 10.1016\/S0090-4295(99)80346-X.","journal-title":"Urology"},{"key":"2792_CR14","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"B Chauffert","year":"2008","unstructured":"Chauffert B, Mornex F, Bonnetain F, et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD\/SFRO study. Ann Oncol. 2008, 19: 1592-9. 10.1093\/annonc\/mdn281.","journal-title":"Ann Oncol"},{"key":"2792_CR15","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1200\/JCO.2004.09.043","volume":"22","author":"A Bamias","year":"2004","unstructured":"Bamias A, Deliveliotis Ch, Fountzilas G, et al: Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic cooperative oncology group. J Clin Oncol. 2004, 22: 2150-54. 10.1200\/JCO.2004.09.043.","journal-title":"J Clin Oncol"},{"key":"2792_CR16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1442-2042.2008.02114.x","volume":"15","author":"N Soga","year":"2008","unstructured":"Soga N, Arima K, Sugimura Y: Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol. 2008, 15: 800-803. 10.1111\/j.1442-2042.2008.02114.x.","journal-title":"Int J Urol"},{"key":"2792_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1046\/j.1442-2042.2001.00286.x","volume":"8","author":"N Sakamoto","year":"2001","unstructured":"Sakamoto N, Naito S, Kumazawa J, et al: Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study. Int J Urology. 2001, 8: 212-16. 10.1046\/j.1442-2042.2001.00286.x.","journal-title":"Int J Urology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-11-297\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:26:27Z","timestamp":1630614387000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-11-297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,14]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2792"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-11-297","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,14]]},"assertion":[{"value":"25 July 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"297"}}